Search Results - "pharmacodynamics"

Pharmacodynamic Evaluation of Shenfu Injection in Rats With Ischemic Heart Failure and Its Effect on Small Molecules Using Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Imaging by Hao Wu, Hao Wu, Zhenfeng Dai, Zhenfeng Dai, Xi Liu, Xi Liu, Ming Lin, Ming Lin, Zeyu Gao, Zeyu Gao, Fang Tian, Fang Tian, Xin Zhao, Xin Zhao, Yi Sun, Yi Sun, Xiaoping Pu, Xiaoping Pu

Connect to this object online.

Evaluation of pharmacokinetic and pharmacodynamic interaction between repaglinide and atazanavir in healthy, diabetic and hepatic impaired rats: possible inhibition of CYP3A, OATP, and P-glycoprotein transporters by Thirumal Eswara Goud, Srinivas Maddi, Nayakanti Devanna, Thatipamula Rajendra Prasad

Connect to this object online.

In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing <i>Enterobacter cloacae</i> and <i>Klebsiella pneumoniae</i> in Murine Pneumonia Model by Mao Hagihara, Hideo Kato, Toshie Sugano, Hayato Okade, Nobuo Sato, Yuichi Shibata, Daisuke Sakanashi, Jun Hirai, Nobuhiro Asai, Hiroyuki Suematsu, Yuka Yamagishi, Hiroshige Mikamo

Connect to this object online.

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients by Jaydeep K. Srimani, Paul M. Diderichsen, Michael J. Hanley, Karthik Venkatakrishnan, Richard Labotka, Neeraj Gupta

Connect to this object online.

Predicting treatment response to vancomycin using bacterial DNA load as a pharmacodynamic marker in premature and very low birth weight neonates: A population PKPD study by Amadou Samb, Rimke De Kroon, Koos Dijkstra, Marre Van Den Brand, Martine Bos, Martine Bos, Frank Van Den Dungen, Agnes Veldkamp, Bram Wilhelm, Timo R. De Haan, Yuma A. Bijleveld, Marceline Tutu Van Furth, Paul Savelkoul, Paul Savelkoul, Noortje Swart, Noortje Swart, Ron Mathot, Mirjam Van Weissenbruch

Connect to this object online.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial by Yu-zhou Gui, Yu-zhou Gui, Wei Wang, Wei Wang, Qing-qing Wu, Qing-qing Wu, Qi-chen Ding, Qi-chen Ding, Hong-jie Qian, Hong-jie Qian, Qiu-bei Lu, Ying-jun Zhang, Yu-lei Zhuang, Li Deng, Ying-lin Zuo, Lin Luo, Jing-ying Jia, Jing-ying Jia

Connect to this object online.

Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus by Hanqing Li, Jiayin Xu, Xiaohong Fan

Connect to this object online.

Corrigendum: Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach by Shuaibing Liu, Ziteng Wang, Xin Tian, Weimin Cai

Connect to this object online.

Urinary Pharmacokinetic and Pharmacodynamic Profiles of Fosfomycin against Extended-Spectrum β-Lactamase-Producing <i>Escherichia coli</i> with Canine Ex Vivo Modeling: A Pilot Study by Kazuki Harada, Takae Shimizu, Koji Kawaguchi, Takeshi Furuhashi, Genki Ishihara

Connect to this object online.

The mechanism and pharmacodynamics of 2-((1H-indol-3-yl)thio/sulfinyl)-N-pheny acetamide derivative as a novel inhibitor against human respiratory syncytial virus by Ningning Cheng, Nan Jiang, Yuanhui Fu, Zhuxin Xu, Xianglei Peng, Jiemei Yu, Shan Cen, Yucheng Wang, Guoning Zhang, Yanpeng Zheng, Jinsheng He

Connect to this object online.

Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem by Maria Sanz Codina, Milo Gatti, Carla Troisi, Giacomo Fornaro, Zeno Pasquini, Filippo Trapani, Andrea Zanoni, Fabio Caramelli, Pierluigi Viale, Federico Pea

Connect to this object online.

Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints by Yiya Wang, Yiya Wang, Ying Zhou, Juefang Ding, Xianjing Li, Fengxue Guo, Jianfei Zhang, Li Ding

Connect to this object online.

A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis by Melissa Palmer, Lee Jennings, Debra G. Silberg, Caleb Bliss, Patrick Martin

Connect to this object online.

Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod by Qiudi Jiang, Yuchen Zhang, Dan Duan, Sylvie Retout, Ruchi Upmanyu, Katerina Glavini, Miriam Triyatni, Yonghong Zhu, Joseph F. Grippo, Yuyan Jin

Connect to this object online.

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP&reg;) Biosimilar, to Those of NESP&reg; After a Single Subcutaneous or Intravenous Administration to Healthy Subjects by Jeon I, Oh J, Kwon YK, Yoon SH, Cho JY, Jang IJ, Yu KS, Lee S

Connect to this object online.

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson&rsquo;s disease, in healthy volunteers by Shin W, Lim KS, Kim MK, Kim HS, Hong J, Jhee S, Kim J, Yoo S, Chung YT, Lee JM, Cho DY

Connect to this object online.

Pharmacokinetics and Pharmacodynamics of Key Components of a Standardized <i>Centella asiatica</i> Product in Cognitively Impaired Older Adults: A Phase 1, Double-Blind, Randomized Clinical Trial by Kirsten M. Wright, Melissa Bollen, Jason David, Alex B. Speers, Mikah S. Brandes, Nora E. Gray, Armando Alcázar Magaña, Christine McClure, Jan F. Stevens, Claudia S. Maier, Joseph F. Quinn, Amala Soumyanath

Connect to this object online.

Effect of CYP3A4 Inhibitors and Inducers on Pharmacokinetics and Pharmacodynamics of Saxagliptin and Active Metabolite M2 in Humans Using Physiological-Based Pharmacokinetic Combined DPP-4 Occupancy by Gang Li, Bowen Yi, Jingtong Liu, Xiaoquan Jiang, Fulu Pan, Wenning Yang, Haibo Liu, Yang Liu, Guopeng Wang

Connect to this object online.

Comparative Biochemical and Pharmacodynamic Analyses of <i>Asarum heterotropoides</i> Fr.... by Huiling Li, Zhiqing Wang, Guangyuan Zhao, Yanhong Wang, Xuanwei Xu, Yingping Wang, Ze Zhang, Guanghui Wang

Connect to this object online.

Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study by Yang E, Yoo H, Jang IJ, Yu KS, Lee S

Connect to this object online.